Trial Profile
Phase 1b/2 Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 May 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Pepinemab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; First in man
- Acronyms CLASSICAL-Lung
- Sponsors Vaccinex
- 21 Apr 2021 Results published in the Vaccinex Media Release.
- 05 Apr 2021 Results published in the Clinical Cancer Research
- 16 Oct 2020 Status changed from active, no longer recruiting to completed.